Pirtobrutinib approved to treat chronic lymphocytic leukemia and small lymphocytic lymphoma
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Pirtobrutinib (Jaypirca), a first-generation noncovalent Bruton tyrosine kinase inhibitor, has received approval to treat relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The drug poses risks for several serious adverse effects, including infections, hemorrhage, cytopenias, cardiac arrythmias, and embryo–fetal toxicity. Nurses should teach patients they will need repeated blood work to assess for laboratory abnormalities.
Fields of Study & Subjects
Chronic Lymphocytic Leukemia Research
Lymphoma Diagnosis and Treatment
Acute Lymphoblastic Leukemia research
Publication details
- Journal / source
- AJN American Journal of Nursing
- Volume
- 126
- Issue
- 4
- Pages
- 24–24
- Publication date
- 26 March 2026
- Language
- EN